News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
256,319 Results
Type
Article (13722)
Company Profile (257)
Press Release (242340)
Section
Business (79156)
Career Advice (147)
Deals (13165)
Drug Delivery (28)
Drug Development (50143)
Employer Resources (31)
FDA (5633)
Job Trends (5103)
News (143581)
Policy (10010)
Tag
Academia (901)
Africa (145)
Allergies (30)
Alliances (21402)
Alzheimer's disease (684)
Antibody-drug conjugate (ADC) (31)
Approvals (5597)
Arizona (38)
Artificial intelligence (29)
Asia (16639)
Australia (2779)
Bankruptcy (96)
Best Places to Work (4346)
Biotechnology (215)
C2C Services and Suppliers (10603)
California (1211)
Canada (493)
Cancer (295)
Career advice (128)
CAR-T (33)
Cell therapy (93)
China (88)
Clinical research (39033)
Collaboration (85)
Colorado (36)
Compensation (39)
Connecticut (42)
COVID-19 (977)
Cystic fibrosis (58)
Data (220)
Diabetes (38)
Diagnostics (1156)
Earnings (28356)
Employer resources (29)
Europe (35676)
Events (45759)
Executive appointments (96)
FDA (5748)
Florida (120)
Funding (98)
Gene editing (28)
Gene therapy (80)
GLP-1 (262)
Government (1051)
Healthcare (6509)
Hotbed/Location (184125)
Illinois (74)
Indiana (43)
Infectious disease (986)
Inflammatory bowel disease (79)
IPO (7134)
Job creations (856)
Job search strategy (124)
Kansas (52)
Layoffs (177)
Legal (1368)
Lung cancer (69)
Maryland (184)
Massachusetts (986)
Medical device (2513)
Medtech (2514)
Mergers & acquisitions (6033)
Metabolic disorders (130)
Michigan (38)
Minnesota (65)
Neuroscience (791)
New Jersey (329)
New York (392)
NextGen Class of 2024 (1975)
Non-profit (837)
North Carolina (325)
Northern California (527)
Obesity (75)
Ohio (62)
Opinion (86)
Parkinson's disease (30)
Patents (35)
Peanut (27)
Pennsylvania (276)
People (24701)
Pharmaceutical (41)
Phase I (13694)
Phase II (18147)
Phase III (11549)
Pipeline (73)
Postmarket research (842)
Preclinical (5767)
Press Release (30)
Rare diseases (102)
Real estate (1405)
Regulatory (8016)
Research institute (928)
South America (206)
Southern California (504)
Startups (1963)
Texas (113)
United States (4642)
Vaccines (132)
Washington State (153)
Weight loss (59)
Date
Today (111)
Last 7 days (430)
Last 30 days (1372)
Last 365 days (21473)
2024 (15028)
2023 (22412)
2022 (26825)
2021 (27807)
2020 (23358)
2019 (16225)
2018 (11739)
2017 (13752)
2016 (11841)
2015 (14350)
2014 (10392)
2013 (7485)
2012 (7532)
2011 (7614)
2010 (7428)
256,319 Results for "celldex therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Celldex Therapeutics to Present at Jefferies 2024 Healthcare Conference
Celldex Therapeutics, Inc. announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET.
June 4, 2024
·
1 min read
Business
Celldex Therapeutics to Present at Upcoming Investor Conferences
September 12, 2024
·
1 min read
Drug Development
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
Celldex Therapeutics, Inc. announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria.
June 2, 2024
·
8 min read
Pharm Country
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. All of the shares to be sold in the offering are to be sold by Celldex.
February 29, 2024
·
4 min read
Business
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 6, 2024
·
11 min read
Pharm Country
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 10:00 a.m. ET.
March 8, 2024
·
3 min read
Pharm Country
Celldex Therapeutics Announces Proposed Public Offering of Common Stock - February 28, 2024
Celldex Therapeutics, Inc. announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering.
February 28, 2024
·
4 min read
Pharm Country
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen’s 44th Annual Health Care Conference.
March 5, 2024
·
3 min read
Drug Development
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell.
May 15, 2024
·
6 min read
Drug Development
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD).
April 17, 2024
·
6 min read
1 of 25,632
Next